Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 954

1.
2.
3.

Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein.

Johnson TR, Rothenberg ME, Graham BS.

J Leukoc Biol. 2008 Sep;84(3):748-59. doi: 10.1189/jlb.0907621. Epub 2008 Jun 2.

9.

CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease.

Olson MR, Varga SM.

J Immunol. 2007 Oct 15;179(8):5415-24.

10.

Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.

Li X, Sambhara S, Li CX, Ettorre L, Switzer I, Cates G, James O, Parrington M, Oomen R, Du RP, Klein M.

Virology. 2000 Mar 30;269(1):54-65.

11.
13.

CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV).

Hancock GE, Heers KM, Smith JD, Scheuer CA, Ibraghimov AR, Pryharski KS.

Vaccine. 2001 Sep 14;19(32):4874-82.

PMID:
11535341
14.

Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.

Castilow EM, Olson MR, Varga SM.

Immunol Res. 2007;39(1-3):225-39. Review.

PMID:
17917067
17.

Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.

Cyr SL, Jones T, Stoica-Popescu I, Brewer A, Chabot S, Lussier M, Burt D, Ward BJ.

Vaccine. 2007 Jul 20;25(29):5378-89. Epub 2007 May 24.

PMID:
17561317

Supplemental Content

Support Center